View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2012	Oct. 20, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Entity Registrant Name	Lilly Eli & Co
Entity Central Index Key	0000059478
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		1,160,452,507

Consolidated Condensed Statements of Operations - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue	$ 5,443.3	$ 6,147.9	$ 16,646.0	$ 18,239.9
Cost of sales	1,203.6	1,338.1	3,548.2	3,746.2
Research and development	1,342.8	1,280.9	3,815.0	3,665.5
Marketing, selling, and administrative	1,757.4	1,917.8	5,536.0	5,746.5
Acquired in-process research and development	0.0	0.0	0.0	388.0
Asset impairments, restructuring, and other special charges	53.3	25.2	77.1	233.8
Other - net, (income) expense	(788.5)	83.4	(726.0)	152.2
Cost of sales, operating expenses, and other-net	3,568.6	4,645.4	12,250.3	13,932.2
Income before income taxes	1,874.7	1,502.5	4,395.7	4,307.7
Income taxes	548.1	266.2	1,134.4	818.2
Net income	$ 1,326.6	$ 1,236.3	$ 3,261.3	$ 3,489.5
Earnings per share - basic and diluted	$ 1.18	$ 1.11	$ 2.92	$ 3.13
Dividends paid per share	$ 0.49	$ 0.49	$ 1.47	$ 1.47

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net income	$ 1,326.6	$ 1,236.3	$ 3,261.3	$ 3,489.5
Other comprehensive income (loss), net of tax	398.3	(496.0)	322.7	164.2
Comprehensive income	$ 1,724.9	$ 740.3	$ 3,584.0	$ 3,653.7

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 30, 2012	Dec. 31, 2011
Current Assets
Cash and cash equivalents	$ 5,319.2	$ 5,922.5
Short-term Investments	1,580.7	974.6
Accounts receivable, net of allowances of $111.0 (2012) and $110.1 (2011)	3,268.2	3,597.7
Other receivables	527.3	640.2
Inventories	2,553.4	2,299.8
Prepaid expenses and other	790.1	813.4
Total current assets	14,038.9	14,248.2
Other Assets
Investments	5,224.3	4,029.8
Goodwill and other intangibles - net	5,031.1	5,128.1
Sundry	2,387.8	2,493.4
Total other assets	12,643.2	11,651.3
Property and Equipment
Land, buildings, equipment, and construction-in-progress	14,944.4	14,594.0
Less accumulated depreciation	(7,305.5)	(6,833.7)
Property and equipment, net	7,638.9	7,760.3
Total assets	34,321.0	33,659.8
Current Liabilities
Short-term borrowings and current maturities of long-term debt	9.1	1,522.3
Accounts payable	1,328.7	1,125.2
Employee compensation	772.7	804.7
Sales rebates and discounts	1,695.6	1,771.3
Dividends payable	0.0	542.3
Income taxes payable	338.2	261.6
Other current liabilities	2,816.4	2,903.5
Total current liabilities	6,960.7	8,930.9
Other Liabilities
Long-term debt	5,510.9	5,464.7
Accrued retirement benefits	2,702.4	3,068.5
Long-term income taxes payable	1,275.1	1,086.3
Other noncurrent liabilities	1,815.0	1,573.8
Total other liabilities	11,303.4	11,193.3
Shareholders' Equity
Common stock	725.8	724.1
Additional paid-in capital	4,919.9	4,886.8
Retained earnings	17,062.2	14,897.8
Employee benefit trust	(3,013.2)	(3,013.1)
Accumulated other comprehensive loss	(3,535.9)	(3,858.6)
Noncontrolling interest	(7.6)	(6.1)
Cost of common stock in treasury	(94.3)	(95.3)
Total shareholders' equity	16,056.9	13,535.6
Total liabilities and shareholders' equity	$ 34,321.0	$ 33,659.8

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2012	Dec. 31, 2011
Accounts receivable, allowances	$ 111.0	$ 110.1

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash Flows from Operating Activities
Net income	$ 3,261.3	$ 3,489.5
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,117.6	1,054.7
Changes in deferred income taxes	206.2	222.0
Stock-based compensation expense	100.3	110.7
Impairment charges, indefinite lived intangibles	16.0	151.0
Acquired in-process research and development, net of tax	0.0	252.2
Income related to prepayment of revenue-sharing obligation	(787.8)	0.0
Other changes in operating assets and liabilities	(271.5)	76.7
Other operating activities, net	60.7	(67.0)
Net Cash Provided by Operating Activities	3,702.8	5,289.8
Cash Flows from Investing Activities
Net purchases of property and equipment	(492.2)	(416.1)
Net change in short-term investments	257.3	545.0
Proceeds from sales and maturities of noncurrent investments	3,557.4	1,082.6
Purchases of noncurrent investments	(5,506.8)	(2,659.3)
Purchase of product rights	(102.0)	(605.7)
Purchase of in-process research and development	0.0	388.0
Cash paid for acquisitions, net of cash acquired	(199.3)	(307.8)
Net change in loan to collaboration partner	165.0	(165.0)
Proceeds from prepayment of revenue-sharing obligation	1,212.1	0.0
Other investing activities, net	(61.8)	(33.3)
Net Cash Used for Investing Activities	(1,170.3)	(2,947.6)
Cash Flows from Financing Activities
Dividends paid	(1,639.2)	(1,636.2)
Net change in short-term borrowings	(15.2)	(28.6)
Repayment of long-term debt	(1,500.0)	(54.6)
Other financing activities, net	0.0	0.4
Net Cash Used for Financing Activities	(3,154.4)	(1,719.0)
Effect of exchange rate changes on cash and cash equivalents	18.6	(18.7)
Net (decrease) increase in cash and cash equivalents	(603.3)	604.5
Cash and cash equivalents at January 1	5,922.5	5,993.2
Cash and Cash Equivalents at September 30	$ 5,319.2	$ 6,597.7

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2012
Accounting Policies [Abstract]
Basis of Presentation [Text Block]	Note 1: Basis of Presentation We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2011. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Implementation of New Financial Accounting Pronouncements	9 Months Ended
	Sep. 30, 2012
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Accounting Changes and Error Corrections [Text Block]	Note 2: Implementation of New Financial Accounting Pronouncements There are no new accounting pronouncements that have had or will have a material impact on our consolidated condensed financial statements.

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References + Details

Acquisitions	9 Months Ended
Acquisitions	Sep. 30, 2012
Business Combinations [Abstract]
Acquisitions [Text Block]	Note 3: Acquisitions On February 17, 2012, we acquired all of the outstanding stock of ChemGen Corporation, a privately-held bioscience company specializing in the development and commercialization of innovative feed-enzyme products that improve the efficiency of poultry, egg, and meat production, for total purchase consideration of $206.9 million in cash. In connection with this acquisition, we preliminarily recorded $151.5 million of marketed product assets, with $55.4 million of other net assets. The final determination may result in asset and liability fair values that differ from the preliminary estimates, but it is not expected that these differences will be material to our consolidated financial statements. On July 7, 2011, we acquired the animal health business of Janssen Pharmaceutica NV, a Johnson & Johnson company, for total purchase consideration of $307.8 million in cash. We obtained a portfolio of more than 50 animal health products. In connection with this acquisition, we recorded $234.4 million of marketed product assets and $29.6 million of acquired in-process research and development (IPR&D) assets, with $43.8 million of other net assets.

Collaborations

9 Months Ended

Sep. 30, 2012

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborations [Text Block]

Note 4: Collaborations

We often enter into collaborative arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These collaborations often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products sold by us pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit-share payments) are included in collaboration and other revenue. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below.

The following table summarizes the composition of our total revenue recognized from all transactions, including collaboration activity:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	5,301.2	$	5,971.7	$	16,170.5	$	17,748.1
Collaboration and other revenue	142.1		176.2		475.5		491.8
Total revenue	$	5,443.3	$	6,147.9	$	16,646.0	$	18,239.9

Exenatide

In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta^® (exenatide injection) and other forms of exenatide such as Bydureon™ (exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of $250.0 million. Amylin also agreed to make future revenue-sharing payments to us in an amount equal to 15.0 percent of its global net sales of exenatide products until Amylin made aggregate payments to us of $1.20 billion plus interest, which would accrue at 9.5 percent. Amylin issued a secured note in the amount of $1.20 billion to us under which any revenue-sharing payments made to us would reduce amounts outstanding under the note. Upon completion of the acquisition of Amylin by Bristol-Myers Squibb in August 2012, Amylin's obligation of $1.26 billion for the revenue-sharing payments and the secured note, including accrued interest, was paid in full, with $1.21 billion representing a prepayment of the obligation. Amylin will also pay a $150.0 million milestone to us contingent upon FDA approval of a once-monthly suspension version of exenatide that is currently in Phase II clinical trials.

Commercial operations were transferred to Amylin in the U.S. at the end of November 2011. Outside the U.S., we anticipate transferring responsibility for commercialization of exenatide to Amylin in substantially all markets during the first half of 2013.

Payments received from Amylin were allocated 65 percent to the U.S., which was treated as a contract termination, and 35 percent to the business outside the U.S., which will be treated as the disposition of a business. The allocation was based upon relative fair values. The revenue-sharing income allocated to the U.S. was recognized as collaboration and other revenue, consistent with our policy for royalty revenue, while the income related to the prepayment of Amylin's obligation allocated to the U.S. was recognized as other-net, (income) expense. All income allocated to the business outside the U.S. will be recognized on a pro rata basis as a gain on the disposition of a business in other-net, (income) expense as control of the business transfers to Amylin market by market during 2013. We expect to recognize a net gain of approximately $490 million in 2013 contingent upon the transfer of the commercial rights outside the United States.

Prior to termination of the collaboration, we and Amylin were co-promoting Byetta in the United States. Amylin was responsible for manufacturing and primarily utilized third-party contract manufacturers to supply Byetta. We supplied Byetta pen delivery devices for Amylin and will continue to do so for a period that will not extend beyond December 31, 2013. We are responsible for certain development costs related to certain clinical trials outside the U.S. that we were conducting as of the date of the termination agreement as well as commercialization costs outside the U.S. until the commercial operations are transferred to Amylin.

Under the terms of our prior arrangement, we reported as collaboration and other revenue our 50 percent share of gross margin on Amylin’s net product sales in the U.S. We reported as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. will continue until those operations transfer to Amylin. Prior to its termination, under the 50/50 profit-sharing arrangement for the U.S., in addition to recording as revenue our 50 percent share of exenatide’s gross margin, we also recorded approximately 50 percent of U.S. related research and development costs and marketing and selling costs in the respective line items on the consolidated condensed statements of operations.

In accordance with the prior arrangement and pursuant to Amylin’s request, we loaned Amylin $165.0 million in the second quarter of 2011. This loan and related accrued interest were paid in full in August 2012.

The following table summarizes the revenue and other income recognized with respect to exenatide:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	49.5	$	46.4	$	151.1	$	131.9
Collaboration and other revenue	4.7		60.3		70.1		180.5
Total revenue	$	54.2	$	106.7	$	221.2	$	312.4

Income related to prepayment of Amylin's obligation ⁽¹⁾	$	787.8	$	—	$	787.8	$	—

¹ Presented in other-net, (income) expense

Erbitux^®

We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Japan, and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). The agreements are expected to expire in 2018, upon which all of the rights with respect to Erbitux in the U.S. and Canada return to us and certain rights with respect to Erbitux outside the U.S. and Canada (excluding Japan) remain with Merck KGaA (Merck). The following table summarizes the revenue recognized with respect to Erbitux:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	6.2	$	16.2	$	69.0	$	61.2
Collaboration and other revenue	80.4		81.1		241.0		240.1
Total revenue	$	86.6	$	97.3	$	310.0	$	301.3

Bristol-Myers Squibb Company

Pursuant to a commercial agreement with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), relating to Erbitux, we are co-developing Erbitux in the U.S. and Canada with BMS, exclusively, and in Japan with BMS and Merck. The companies have jointly agreed to expand the investment in the ongoing clinical development plan for Erbitux to further explore its use in additional tumor types. Under this arrangement, Erbitux research and development and other costs are shared by both companies according to a predetermined ratio.

Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreement. Collaborative reimbursements received by us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.

We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the territory, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales.

Merck KGaA

A development and license agreement with Merck with respect to Erbitux granted Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and co-exclusive rights with BMS and us in Japan. Merck also has rights to manufacture Erbitux for supply in its territory. We receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Collaborative reimbursements received for research and for development; and marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.

Necitumumab

The commercial agreement with BMS described above includes the co-development and co-commercialization of necitumumab, which is currently in Phase III clinical testing for squamous non-small cell lung cancer. We and BMS share the cost of developing and potentially commercializing necitumumab in the U.S., Canada, and Japan. We maintain exclusive rights to necitumumab in all other markets. We will fund 45 percent of the development costs for studies that will be used only in the U.S., and 72.5 percent for global studies. We will be responsible for the manufacturing of API, and BMS will be responsible for manufacturing the finished product. We could receive a payment of $250.0 million upon approval in the United States. In the U.S. and Canada, BMS will record sales and we will receive 45 percent of the profits for necitumumab, while we will provide 50 percent of the selling effort. In Japan, we and BMS will share costs and profits evenly.

Effient^®

We are in a collaborative arrangement with Daiichi Sankyo Company, Limited (D-S) to develop, market, and promote Effient. We and D-S have agreed to co-promote in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. D-S has exclusive marketing rights in Japan. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay D-S a royalty specific to these territories. Profit-share payments made to D-S are recorded as marketing, selling, and administrative expenses. All royalties paid to D-S and the third-party manufacturer are recorded in cost of sales.

Diabetes Collaboration

In January 2011, we and Boehringer Ingelheim (Boehringer) entered into a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Included are Boehringer’s two oral diabetes agents, linagliptin and empagliflozin. Subsequently in 2011, linagliptin was approved and launched in the U.S. (tradename Tradjenta™), Japan (tradename Trazenta^®), Europe (tradename Trajenta^®), and other countries. Empagliflozin is currently in Phase III clinical testing. Also included in the agreement are our new insulin glargine product and our novel basal insulin analog, both of which began Phase III clinical testing in the second half of 2011; and an option granted to Boehringer to co-develop and co-commercialize our anti-TGF-beta monoclonal antibody, which is currently in Phase II clinical testing. Under the terms of the agreement, we made an initial one-time payment to Boehringer of $388.0 million and recorded an acquired IPR&D charge, which was included as expense in the first quarter of 2011 and is deductible for tax purposes.

In connection with the approval of linagliptin in the U.S., Japan, and Europe, in 2011 we paid $478.7 million in success-based regulatory milestones, all of which were capitalized as intangible assets and are being amortized to cost of sales. We may pay up to €300.0 million in additional success-based regulatory milestones for empagliflozin. We will be eligible to receive up to a total of $650.0 million in success-based regulatory milestones on our two insulin products. Should Boehringer elect to opt in to the Phase III development and potential commercialization of the anti-TGF-beta monoclonal antibody, we would be eligible for up to $525.0 million in opt-in and success-based regulatory milestone payments. The companies share ongoing development costs equally. The companies also share in the commercialization costs and gross margin for any product resulting from the collaboration that receives regulatory approval. We record our portion of the gross margin as collaboration and other revenue, and we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. Revenue related to this collaboration was not significant for the nine months ended September 30, 2012 and 2011, respectively.

Cymbalta^®

Boehringer Ingelheim

We were in a collaborative arrangement with Boehringer to jointly develop, market, and promote Cymbalta (duloxetine) outside the U.S. and Japan. Pursuant to the terms of the agreement, we generally shared equally in development, marketing, and selling expenses, and paid Boehringer a commission on sales in the co-promotion territories. We manufactured the product for all territories. Reimbursements or payments for the cost sharing of marketing, selling, and administrative expenses were recorded in the respective expense line items in the consolidated condensed statements of operations. The commission paid to Boehringer was recorded in marketing, selling, and administrative expenses. In March 2010, the parties agreed to terminate this agreement, and we reacquired the exclusive rights to develop and market duloxetine for all indications in countries outside the U.S. and Japan. In connection with the termination, we paid Boehringer approximately $400 million and will also pay to Boehringer a percentage of our sales of duloxetine in these countries through the end of 2012 as consideration for the rights acquired. We record these costs as intangible assets that are amortized to marketing, selling, and administrative expenses using the straight-line method over the life of the original agreement, which is through the third quarter of 2015.

Quintiles

We were in a collaborative arrangement with Quintiles Transnational Corp. (Quintiles) to jointly market and promote Cymbalta in the U.S. Pursuant to the terms of the agreement, Quintiles shared in the costs to co-promote Cymbalta with us and received a commission based upon net product sales. Quintiles’ obligation to promote Cymbalta expired during 2009, and we incurred a lower commission for three years after completion of their promotion efforts. The commissions paid to Quintiles are recorded in marketing, selling, and administrative expenses.

Solanezumab

We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby TPG funded a portion of the Phase III development of solanezumab. Under the agreement, TPG’s obligation to fund solanezumab costs was not material and ended in the first half of 2011. In exchange for their funding, TPG may receive success-based sales milestones totaling approximately $70 million and mid-single digit royalties that are contingent upon the successful development of solanezumab. The royalties relating to solanezumab would be paid for approximately eight years after launch of a product.

Baricitinib

In December 2009, we entered into a worldwide license and collaboration agreement with Incyte Corporation (Incyte) to acquire development and commercialization rights to its JAK inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. The agreement calls for payments of up to $515.0 million associated with certain development and regulatory milestones as well as an additional $150.0 million of potential sales-based milestones. Incyte also has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. The agreement also provides Incyte with an option to co-promote in the United States. In 2010, Incyte exercised its option to co-develop baricitinib in rheumatoid arthritis. We made development milestone payments of $49.0 million in 2010 related to Phase II trials of baricitinib and would pay an additional $50.0 million upon initiation of Phase III trials for rheumatoid arthritis.

Summary of Collaboration-Related Commission and Profit-Share Payments

The aggregate amount of commission and profit-share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above was $65.2 million and $58.6 million in the quarters ended September 30, 2012 and 2011, respectively, and $211.0 million and $155.5 million in the nine months ended September 30, 2012 and 2011, respectively.

Asset Impairments, Restructuring, and Other Special Charges	9 Months Ended
	Sep. 30, 2012
Other Cost and Expense Disclosure, Operating [Abstract]
Asset Impairments, Restructuring, And Other Special Charges [Text Block]	Note 5: Asset Impairments, Restructuring, and Other Special Charges We recognized asset impairments, restructuring, and other special charges of $53.3 million and $77.1 million in the third quarter and first nine months of 2012, respectively, and $25.2 million and $233.8 million in the third quarter and first nine months of 2011, respectively. The 2012 charges primarily relate to the recognition of an asset impairment related to the decision to stop development of a delivery device platform during the third quarter, and a charge in the first quarter of 2012 resulting from a change in our estimates of returned product related to the withdrawal of Xigris^® from the market during the fourth quarter of 2011. The 2011 charges primarily related to severance costs.

Financial Instruments

9 Months Ended

Sep. 30, 2012

Fair Value Disclosures [Abstract]

Financial Instruments [Text Block]

Note 6: Financial Instruments

Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we limit the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

Accounting Policy for Risk-Management Instruments

Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.

For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized currently in earnings during the period of change.

We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are entered into with the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other — net, (income) expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2012, we had outstanding foreign currency forward commitments to purchase 863.9 million U.S. dollars and sell 669.9 million euro, commitments to purchase 892.2 million euro and sell 1.16 billion U.S. dollars, and commitments to purchase 202.0 million British pounds and sell 252.4 million euro, which will all settle within 30 days.

In the normal course of business, our operations are exposed to fluctuations in interest rates. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.

Interest rate swaps or collars that convert our fixed-rate debt or investments to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt or investments to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. At September 30, 2012, approximately 100 percent of our total debt is at a fixed rate. We have converted approximately 60 percent of our fixed-rate debt to floating rates through the use of interest rate swaps.

We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.

The Effect of Risk-Management Instruments on the Consolidated Condensed Statement of Operations

The following effects of risk-management instruments were recognized in other—net, (income) expense:



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Dollars in millions)
Fair value hedges
Effect from hedged fixed-rate debt	$	12.1		$	245.4		$	43.8		$	255.7
Effect from interest rate contracts	(12.1		)	(245.4		)	(43.8		)	(255.7		)
Cash flow hedges
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	2.3			2.3			6.7			6.7
Net gains on foreign currency exchange contracts not designated as hedging instruments	(23.7		)	(51.7		)	(38.5		)	(1.0		)

The effective portion of net gains on equity contracts in designated cash flow hedging relationships recorded in other comprehensive income (loss) was $15.5 million and $41.2 million for the three and nine months ended September 30, 2011, respectively. There have been no equity contracts in designated cash flow hedging relationships in 2012.

During the next 12 months, we expect to reclassify from accumulated other comprehensive loss to earnings $9.0 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on our floating rate debt.

During the three and nine months ended September 30, 2012 and 2011, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.

Fair Value of Financial Instruments

The following tables summarize certain fair value information at September 30, 2012 and December 31, 2011 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:



					Fair Value Measurements Using
Description	Carrying Amount		Amortized Cost		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)	Fair Value
	(Dollars in millions)
September 30, 2012
Cash and cash equivalents	$	5,319.2	$	5,319.2	$	5,235.3	$	83.9	$	$	5,319.2

Short-term investments
U.S. government and agencies	$	61.0	$	61.0	$	61.0	$		$	$	61.0
Corporate debt securities	1,509.1		1,507.1				1,509.1			1,509.1
Other securities	10.6		10.6				10.6			10.6
Short-term investments	$	1,580.7	$	1,578.7

Noncurrent investments
U.S. government and agencies	$	1,124.1	$	1,121.1	$	885.7	$	238.4	$	$	1,124.1
Corporate debt securities	2,623.8		2,593.2				2,623.8			2,623.8
Mortgage-backed	401.6		405.3				401.6			401.6
Asset-backed	676.1		692.5				676.1			676.1
Other securities	3.3		3.3				3.3			3.3
Marketable equity	183.4		83.0		183.4					183.4
Equity method and other investments⁽¹⁾	212.0		212.0
Noncurrent investments	$	5,224.3	$	5,110.4

December 31, 2011
Cash and cash equivalents	$	5,922.5	$	5,922.5	$	5,264.6	$	657.9	$	$	5,922.5

Short-term investments
U.S. government and agencies	$	362.3	$	362.3	$	351.3	$	11.0	$	$	362.3
Corporate debt securities	600.7		601.1				600.7			600.7
Other securities	11.6		11.6				11.6			11.6
Short-term investments	$	974.6	$	975.0

Noncurrent investments
U.S. government and agencies	$	908.8	$	901.3	$	673.5	$	235.3	$	$	908.8
Corporate debt securities	2,081.3		2,093.3				2,081.3			2,081.3
Mortgage-backed	443.8		479.1				443.8			443.8
Asset-backed	245.0		253.2				245.0			245.0
Other securities	10.0		11.9				8.7		1.3	10.0
Marketable equity	180.8		107.5		180.8					180.8
Equity method and other investments⁽¹⁾	160.1		160.1
Noncurrent investments	$	4,029.8	$	4,006.4

¹ Fair value not applicable



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
	(Dollars in millions)
Long-term debt, including current portion
September 30, 2012	$	(5,520.0	)	$	$	(6,072.2	)	$	$	(6,072.2	)
December 31, 2011	$	(6,981.5	)	$	$	(7,451.5	)	$	$	(7,451.5	)



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
	(Dollars in millions)
September 30, 2012
Risk-management instruments
Interest rate contracts designated as hedging instruments
Sundry	$	581.7		$	$	581.7		$	$	581.7
Foreign exchange contracts not designated as hedging instruments
Other receivables	7.0				7.0				7.0
Other current liabilities	(18.4		)		(18.4		)		(18.4		)

December 31, 2011
Risk-management instruments
Interest rate contracts designated as hedging instruments
Other receivables	$	6.1		$	$	6.1		$	$	6.1
Sundry	531.7				531.7				531.7
Foreign exchange contracts not designated as hedging instruments
Other receivables	16.2				16.2				16.2
Other current liabilities	(25.9		)		(25.9		)		(25.9		)

The fair value of the contingent consideration liability related to prior acquisitions, a Level 3 measurement in the fair value hierarchy, was $66.9 million and $121.6 million as of September 30, 2012 and December 31, 2011, respectively. The decrease in the fair value of the contingent consideration was primarily due to a $50.0 million approval milestone paid for Amyvid™ in the second quarter of 2012.

We determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available.

Approximately $5.44 billion of our investments in debt securities, measured at fair value, will mature within five years.

A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:



	September 30, 2012		December 31, 2011
	(Dollars in millions)
Unrealized gross gains	$	150.6	$	103.0
Unrealized gross losses	34.7		80.0
Fair value of securities in an unrealized gain position	5,050.6		2,498.9
Fair value of securities in an unrealized loss position	942.3		2,164.4

Other-than-temporary impairment losses on fixed income securities of $0.8 million and $8.2 million were recognized in the statement of operations for the three and nine months ended September 30, 2012, respectively, compared with $10.9 million and $17.9 million for the same periods in 2011. The amount of credit losses represents the difference between the present value of cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit loss were the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.

The securities in an unrealized loss position include fixed-rate debt securities of varying maturities. The value of fixed income securities is sensitive to changes in the yield curve and other market conditions. Approximately 85 percent of the securities in a loss position are investment-grade debt securities. At this time, there is no indication of default on interest or principal payments for debt securities other than those for which an other-than-temporary impairment charge has been recorded. We do not intend to sell and it is not more likely than not we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and we have concluded that no additional other-than-temporary loss is required to be charged to earnings as of September 30, 2012.

Activity related to our available-for-sale investment portfolio was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Proceeds from sales	$	1,698.8	$	775.7	$	5,334.1	$	1,274.2
Realized gross gains on sales	43.1		25.6		70.0		113.6
Realized gross losses on sales	2.2		2.5		7.4		7.6

Realized gains and losses on sales of available-for-sale securities are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2012
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Stock-Based Compensation [Text Block]	Note 7: Stock-Based Compensation Our stock-based compensation expense consists primarily of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognized pretax stock-based compensation cost of $34.4 million and $36.5 million in the third quarter of 2012 and 2011, respectively. In the first nine months of 2012 and 2011, we recognized pretax stock-based compensation expense of $100.3 million and $110.7 million, respectively. PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain earnings per share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. As of September 30, 2012, the total remaining unrecognized compensation cost related to nonvested PAs amounted to $29.9 million, which will be amortized over the weighted-average remaining requisite service period of approximately 12 months. SVAs are granted to officers and management and are payable in shares of common stock at the end of a three-year period. The number of shares actually issued varies depending on our stock price at the end of the three-year vesting period compared to pre-established target prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. As of September 30, 2012, the total remaining unrecognized compensation cost related to nonvested SVAs amounted to $60.1 million, which will be amortized over the weighted-average remaining requisite service period of approximately 22 months. RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. As of September 30, 2012, the total remaining unrecognized compensation cost related to nonvested RSUs amounted to $66.5 million, which will be amortized over the weighted-average remaining requisite service period of 23 months.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Shareholders' Equity	9 Months Ended
Shareholders' Equity	Sep. 30, 2012
Stockholders' Equity Note [Abstract]
Shareholders' Equity [Text Block]	Note 8: Shareholders’ Equity As of September 30, 2012, we have $419.2 million remaining to purchase of our previously announced $3.00 billion share repurchase program. We did not acquire any shares pursuant to this program during the first nine months of 2012. During the second quarter, the board of directors authorized the resumption of this share repurchase program. We expect to complete this program during the remainder of 2012.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Earnings Per Share	9 Months Ended
Earnings Per Share	Sep. 30, 2012
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 9: Earnings Per Share Unless otherwise noted in the footnotes, all per-share amounts are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of all potentially dilutive common shares (primarily contingently issuable shares and unexercised stock options).

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2012
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 10: Income Taxes We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in major taxing jurisdictions for years before 2007. The U.S. examination of certain matters related to tax years 2008-2009 that were not settled as part of previous examinations remains in progress. Because this examination still largely remains in the informational stage, the resolution of all issues in this audit period will likely extend beyond the next 12 months.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Retirement Benefits

9 Months Ended

Sep. 30, 2012

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

Retirement Benefits [Text Block]

Note 11: Retirement Benefits

Net pension and retiree health benefit expense included the following components:



	Defined Benefit Pension Plans
	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Dollars in millions)
Components of net periodic benefit cost
Service cost	$	66.7		$	57.7		$	193.8		$	174.7
Interest cost	113.0			111.8			338.7			335.8
Expected return on plan assets	(171.2		)	(171.9		)	(512.6		)	(515.2		)
Amortization of prior service cost	0.8			2.2			2.5			6.9
Recognized actuarial loss	71.4			50.4			213.3			149.2
Net periodic benefit cost	$	80.7		$	50.2		$	235.7		$	151.4



	Retiree Health Benefit Plans
	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Dollars in millions)
Components of net periodic benefit cost
Service cost	$	16.1		$	14.4		$	48.4		$	43.1
Interest cost	28.6			29.5			85.6			88.6
Expected return on plan assets	(31.8		)	(31.9		)	(95.4		)	(95.7		)
Amortization of prior service cost	(8.8		)	(10.7		)	(26.3		)	(32.2		)
Recognized actuarial loss	24.6			22.2			72.9			66.5
Net periodic benefit cost	$	28.7		$	23.5		$	85.2		$	70.3

On a global basis, we have contributed approximately $60 million required to satisfy minimum funding requirements to our defined benefit pension plans in 2012. In addition, we have contributed approximately $340 million of discretionary funding to our global post-retirement benefit plans in 2012. During the remainder of 2012, we expect to make contributions to our defined benefit pension plans of approximately $10 million to satisfy minimum funding requirements. We do not anticipate making any additional discretionary contributions in 2012.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Contingencies	9 Months Ended
Contingencies	Sep. 30, 2012
Loss Contingency, Information about Litigation Matters [Abstract]
Contingencies [Text Block]	Note 12: Contingencies We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as specifically noted below with respect to the Alimta^® Hatch-Waxman Act patent challenges, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period. Patent Litigation We are engaged in U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Hatch-Waxman Act (the Drug Price Competition and Patent Term Restoration Act of 1984). Teva Parenteral Medicines, Inc. (Teva); APP Pharmaceuticals, LLC (APP); and Barr Laboratories, Inc. (Barr) each submitted ANDAs seeking approval to market generic versions of Alimta prior to the expiration of the relevant U.S. patents and data-based pediatric exclusivity period (compound patent licensed from the Trustees of Princeton University and expiring in 2017, concomitant nutritional supplement use patent expiring in 2022) and alleging the patents are invalid. We, along with Princeton, filed lawsuits in the U.S. District Court for the District of Delaware against Teva, APP, and Barr seeking rulings that the compound patent is valid and infringed. In July 2011, the district court entered judgment in our favor, upholding that patent’s validity. In August 2012, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the district court's judgment in our favor. Teva and APP have filed a petition for en banc review of the CAFC's panel decision. The CAFC has not yet ruled on the defendants' petition. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva Hrvatska D.O.O., and Barr seeking rulings that our concomitant nutritional supplement use patent is valid and infringed. Trial in this case is scheduled to begin in August 2013. In January 2012 and April 2012, we filed similar lawsuits against Accord Healthcare Inc. and Apotex Inc., respectively. We believe the Hatch-Waxman challenges to the Alimta patents are without merit and expect to prevail in this litigation. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market. Zyprexa^® Litigation We are a defendant in approximately 10 Zyprexa product liability lawsuits in the U.S. covering approximately 75 plaintiffs. The lawsuits allege a variety of injuries from the use of Zyprexa, with the majority alleging that the product caused or contributed to diabetes or high blood-glucose levels. The claims seek substantial compensatory and punitive damages and typically accuse us of inadequately testing for and warning about side effects of Zyprexa. Many of the claims also allege that we improperly promoted the drug. We are prepared to continue our vigorous defense of Zyprexa in all these lawsuits and claims. Byetta Litigation We have been named as a defendant in approximately 115 lawsuits involving approximately 500 plaintiffs, primarily seeking to recover damages for pancreatitis experienced by patients prescribed Byetta. We are aware of approximately 500 additional claimants who have not yet filed suit. Approximately 100 of these lawsuits, covering about 485 plaintiffs, are filed in California and coordinated in a Los Angeles Superior Court. We and Amylin are currently scheduled for trial in two separate single-plaintiff cases in the first half of 2013, the first of which is currently scheduled to begin in February. We believe these claims are without merit and are prepared to defend against them vigorously. Diethylstilbestrol Litigation In approximately 90 U.S. lawsuits against us involving approximately 90 claimants, plaintiffs seek to recover damages on behalf of children or grandchildren of women who were prescribed diethylstilbestrol (DES) during pregnancy in the 1950s and 1960s. Approximately 80 of these claimants allege that they were indirectly exposed in utero to the medicine and later developed breast cancer as a consequence. Five cases involving five plaintiffs who developed breast cancer are scheduled for trial in the U.S. District Court of Massachusetts in January 2013. We believe these claims are without merit and are prepared to defend against them vigorously. Product Liability Insurance Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. In the past several years, we have been unable to obtain product liability insurance due to a very restrictive insurance market. Therefore, for substantially all of our currently marketed products, we have been and expect that we will continue to be completely self-insured for future product liability losses. The DES claims are covered by insurance, subject to deductibles and coverage limits. There is no assurance that we will be able to fully collect from our insurance carriers in the future.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Other-Net, Expense (Income)

9 Months Ended

Sep. 30, 2012

Nonoperating Income (Expense) [Abstract]

Other - Net, Expense (Income) [Text Block]

Note 13: Other - Net, (Income) Expense

Other–net, (income) expense comprised the following:



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Dollars in millions)
Income related to prepayment of Amylin's obligation (Note 4)	$	(787.8	)	$	—		$	(787.8	)	$	—
Interest expense	47.0			45.0			135.3			135.9
Interest income	(25.7		)	(22.2		)	(79.0		)	(55.5		)
Other	(22.0		)	60.6			5.5			71.8
Other-net, (income) expense	$	(788.5	)	$	83.4		$	(726.0	)	$	152.2

Other-net, income of $788.5 million and $726.0 million for the third quarter and the first nine months of 2012, respectively, is primarily related to the income recognized from the early payment of the exenatide revenue-sharing obligation by Amylin. See Note 4 for additional information.

Other-net, expense of $152.2 million for the first nine months of 2011 is primarily related to the partial impairment of Amyvid and liprotamase, partially offset by gains on the disposition of investment securities. In the third quarter of 2011, we recognized an expense related to the partial impairment of Amyvid (florbetapir), an acquired IPR&D asset, due to a delay in the expected product launch and lower sales projections during the early part of the product's expected life cycle, resulting in a reduction to the fair value of Amyvid. In the second quarter of 2011, we received a complete response letter from the FDA for the NDA for liprotamase, an acquired IPR&D asset, which communicated the need for us to conduct an additional clinical trial prior to a resubmission, resulting in a reduction to the fair value of liprotamase.

Financial Instruments (Policies)	9 Months Ended
Financial Instruments (Policies)	Sep. 30, 2012
Fair Value Disclosures [Abstract]
Description of Derivative Risk Management Policy	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Policy for Risk-Management Instruments</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized currently in earnings during the period of change.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are entered into with the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">—</font><font style="font-family:Arial;font-size:10pt;"> net, (income) expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</font></div></div>

- Definition

Description of the entity's objectives and strategies pertaining to the use of derivative instruments and nonderivative hedging instruments in the context of the entity's overall risk management profile, and the risks associated with the use of derivatives. Indicates the purpose of derivative instruments not used for hedging purposes. Qualitative disclosures that describe the entity's objectives and strategies for holding derivatives in the context of an entity's overall risk management profile.

+ References + Details

Segment Information (Tables)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Segment Information [Text Block]

Worldwide revenue by category was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Revenue — to unaffiliated customers:
Pharmaceutical products
Neuroscience	$	1,815.8	$	2,488.0	$	5,544.0	$	7,547.1
Endocrinology	1,646.1		1,692.9		5,041.2		4,965.4
Oncology	791.7		817.8		2,442.4		2,483.5
Cardiovascular	650.9		630.1		1,936.4		1,852.5
Other pharmaceuticals	59.4		68.1		199.6		181.0
Total pharmaceutical products	4,963.9		5,696.9		15,163.6		17,029.5
Animal health	479.4		451.0		1,482.4		1,210.4
Total revenue	$	5,443.3	$	6,147.9	$	16,646.0	$	18,239.9

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Collaborations (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the composition of our total revenue recognized from all transactions, including collaboration activity:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	5,301.2	$	5,971.7	$	16,170.5	$	17,748.1
Collaboration and other revenue	142.1		176.2		475.5		491.8
Total revenue	$	5,443.3	$	6,147.9	$	16,646.0	$	18,239.9

Erbitux [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the revenue recognized with respect to Erbitux:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	6.2	$	16.2	$	69.0	$	61.2
Collaboration and other revenue	80.4		81.1		241.0		240.1
Total revenue	$	86.6	$	97.3	$	310.0	$	301.3

Exenatide [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the revenue and other income recognized with respect to exenatide:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	49.5	$	46.4	$	151.1	$	131.9
Collaboration and other revenue	4.7		60.3		70.1		180.5
Total revenue	$	54.2	$	106.7	$	221.2	$	312.4

Income related to prepayment of Amylin's obligation ⁽¹⁾	$	787.8	$	—	$	787.8	$	—

¹ Presented in other-net, (income) expense

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2012

Fair Value Disclosures [Abstract]

Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following effects of risk-management instruments were recognized in other—net, (income) expense:



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Dollars in millions)
Fair value hedges
Effect from hedged fixed-rate debt	$	12.1		$	245.4		$	43.8		$	255.7
Effect from interest rate contracts	(12.1		)	(245.4		)	(43.8		)	(255.7		)
Cash flow hedges
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	2.3			2.3			6.7			6.7
Net gains on foreign currency exchange contracts not designated as hedging instruments	(23.7		)	(51.7		)	(38.5		)	(1.0		)

Fair Value, Assets Measured on Recurring Basis [Table Text Block]



					Fair Value Measurements Using
Description	Carrying Amount		Amortized Cost		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)	Fair Value
	(Dollars in millions)
September 30, 2012
Cash and cash equivalents	$	5,319.2	$	5,319.2	$	5,235.3	$	83.9	$	$	5,319.2

Short-term investments
U.S. government and agencies	$	61.0	$	61.0	$	61.0	$		$	$	61.0
Corporate debt securities	1,509.1		1,507.1				1,509.1			1,509.1
Other securities	10.6		10.6				10.6			10.6
Short-term investments	$	1,580.7	$	1,578.7

Noncurrent investments
U.S. government and agencies	$	1,124.1	$	1,121.1	$	885.7	$	238.4	$	$	1,124.1
Corporate debt securities	2,623.8		2,593.2				2,623.8			2,623.8
Mortgage-backed	401.6		405.3				401.6			401.6
Asset-backed	676.1		692.5				676.1			676.1
Other securities	3.3		3.3				3.3			3.3
Marketable equity	183.4		83.0		183.4					183.4
Equity method and other investments⁽¹⁾	212.0		212.0
Noncurrent investments	$	5,224.3	$	5,110.4

December 31, 2011
Cash and cash equivalents	$	5,922.5	$	5,922.5	$	5,264.6	$	657.9	$	$	5,922.5

Short-term investments
U.S. government and agencies	$	362.3	$	362.3	$	351.3	$	11.0	$	$	362.3
Corporate debt securities	600.7		601.1				600.7			600.7
Other securities	11.6		11.6				11.6			11.6
Short-term investments	$	974.6	$	975.0

Noncurrent investments
U.S. government and agencies	$	908.8	$	901.3	$	673.5	$	235.3	$	$	908.8
Corporate debt securities	2,081.3		2,093.3				2,081.3			2,081.3
Mortgage-backed	443.8		479.1				443.8			443.8
Asset-backed	245.0		253.2				245.0			245.0
Other securities	10.0		11.9				8.7		1.3	10.0
Marketable equity	180.8		107.5		180.8					180.8
Equity method and other investments⁽¹⁾	160.1		160.1
Noncurrent investments	$	4,029.8	$	4,006.4

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
	(Dollars in millions)
Long-term debt, including current portion
September 30, 2012	$	(5,520.0	)	$	$	(6,072.2	)	$	$	(6,072.2	)
December 31, 2011	$	(6,981.5	)	$	$	(7,451.5	)	$	$	(7,451.5	)

Fair Value, by Balance Sheet Grouping [Table Text Block]



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
	(Dollars in millions)
September 30, 2012
Risk-management instruments
Interest rate contracts designated as hedging instruments
Sundry	$	581.7		$	$	581.7		$	$	581.7
Foreign exchange contracts not designated as hedging instruments
Other receivables	7.0				7.0				7.0
Other current liabilities	(18.4		)		(18.4		)		(18.4		)

December 31, 2011
Risk-management instruments
Interest rate contracts designated as hedging instruments
Other receivables	$	6.1		$	$	6.1		$	$	6.1
Sundry	531.7				531.7				531.7
Foreign exchange contracts not designated as hedging instruments
Other receivables	16.2				16.2				16.2
Other current liabilities	(25.9		)		(25.9		)		(25.9		)

Available-for-sale Securities [Table Text Block]



	September 30, 2012		December 31, 2011
	(Dollars in millions)
Unrealized gross gains	$	150.6	$	103.0
Unrealized gross losses	34.7		80.0
Fair value of securities in an unrealized gain position	5,050.6		2,498.9
Fair value of securities in an unrealized loss position	942.3		2,164.4

Gain (Loss) on Investments [Table Text Block]

Activity related to our available-for-sale investment portfolio was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Proceeds from sales	$	1,698.8	$	775.7	$	5,334.1	$	1,274.2
Realized gross gains on sales	43.1		25.6		70.0		113.6
Realized gross losses on sales	2.2		2.5		7.4		7.6

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References + Details

- Definition

Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13476-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13467-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 19
-Subparagraph a, b, c(1), d(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 14
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15
-Subparagraph b-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 18
-Subparagraph c(2), d, e, f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph a, c(1), c(2), c(3), d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

- Definition

Tabular disclosure of the realized and unrealized gains and losses reported in the statement of income which have resulted from the sale and holding of marketable securities, respectively, as well as the sale or disposal of cost method investments. Such amounts would include realized gains and losses on the sale or disposal of trading, available-for-sale, and held-to-maturity securities, unrealized gains and losses on trading securities, unrealized gains and losses on available-for-sale and held-to-maturity securities transferred to the trading securities category, realized gains and losses on the sale or disposal of cost method investments, and losses recognized for other than temporary impairments (OTTI) of such investments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (c)-(e)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.M)
-URI http://asc.fasb.org/extlink&oid=6784337&loc=d3e87990-122713

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 7, 13, 16, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 21
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section M

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Retirement Benefits (Tables)

9 Months Ended

Sep. 30, 2012

Pension Plans, Defined Benefit [Member]

Schedule of Net Benefit Costs [Table Text Block]

Net pension and retiree health benefit expense included the following components:



	Defined Benefit Pension Plans
	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Dollars in millions)
Components of net periodic benefit cost
Service cost	$	66.7		$	57.7		$	193.8		$	174.7
Interest cost	113.0			111.8			338.7			335.8
Expected return on plan assets	(171.2		)	(171.9		)	(512.6		)	(515.2		)
Amortization of prior service cost	0.8			2.2			2.5			6.9
Recognized actuarial loss	71.4			50.4			213.3			149.2
Net periodic benefit cost	$	80.7		$	50.2		$	235.7		$	151.4

Other Postretirement Benefit Plans, Defined Benefit [Member]

Schedule of Net Benefit Costs [Table Text Block]



	Retiree Health Benefit Plans
	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Dollars in millions)
Components of net periodic benefit cost
Service cost	$	16.1		$	14.4		$	48.4		$	43.1
Interest cost	28.6			29.5			85.6			88.6
Expected return on plan assets	(31.8		)	(31.9		)	(95.4		)	(95.7		)
Amortization of prior service cost	(8.8		)	(10.7		)	(26.3		)	(32.2		)
Recognized actuarial loss	24.6			22.2			72.9			66.5
Net periodic benefit cost	$	28.7		$	23.5		$	85.2		$	70.3

Other - Net, Expense (Income) (Tables)

9 Months Ended

Sep. 30, 2012

Nonoperating Income (Expense) [Abstract]

Schedule of Other Nonoperating Income (Expense) [Table Text Block]

Other–net, (income) expense comprised the following:



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Dollars in millions)
Income related to prepayment of Amylin's obligation (Note 4)	$	(787.8	)	$	—		$	(787.8	)	$	—
Interest expense	47.0			45.0			135.3			135.9
Interest income	(25.7		)	(22.2		)	(79.0		)	(55.5		)
Other	(22.0		)	60.6			5.5			71.8
Other-net, (income) expense	$	(788.5	)	$	83.4		$	(726.0	)	$	152.2

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Segment Information (Details) - USD ($) $ in Millions	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue	$ 5,443.3	$ 6,147.9	$ 16,646.0	$ 18,239.9
Segment Reporting Information, Income (Loss) before Income Taxes	1,874.7	1,502.5	4,395.7	4,307.7
Neuroscience [Member]
Segment Reporting Information, Revenue	1,815.8	2,488.0	5,544.0	7,547.1
Endocrinology [Member]
Segment Reporting Information, Revenue	1,646.1	1,692.9	5,041.2	4,965.4
Oncology [Member]
Segment Reporting Information, Revenue	791.7	817.8	2,442.4	2,483.5
Cardiovascular [Member]
Segment Reporting Information, Revenue	650.9	630.1	1,936.4	1,852.5
Animal health [Member]
Segment Reporting Information, Income (Loss) before Income Taxes	106.0	93.0	370.0	228.0
Segment Reporting Information, Revenue	479.4	451.0	1,482.4	1,210.4
Other pharmaceuticals [Member]
Segment Reporting Information, Revenue	59.4	68.1	199.6	181.0
Pharmaceutical products, total [Member]
Segment Reporting Information, Revenue	$ 4,963.9	$ 5,696.9	$ 15,163.6	$ 17,029.5

Acquisitions (Details) $ in Millions	Feb. 17, 2012 USD ($)	Jul. 07, 2011 USD ($)
ChemGen Corporation [Member]
Business Acquisition, Cost of Acquired Entity, Purchase Price, Total	$ 206.9
Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets	151.5
Business Acquisition, Purchase Price Allocation, Net Tangible Assets	$ 55.4
Janssen Pharmaceutica NV (J&J) [Member]
Business Acquisition, Cost of Acquired Entity, Purchase Price, Total		$ 307.8
Business Acquisition, Products or Other Assets Acquired		50
Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets		$ 234.4
Business Acquisition, Purchase Price Allocation, Intangible Assets Not Amortizable		29.6
Business Acquisition, Purchase Price Allocation, Net Tangible Assets		$ 43.8

Collaborations (Details) € in Millions, $ in Millions	1 Months Ended			3 Months Ended								9 Months Ended		10 Months Ended	12 Months Ended
Collaborations (Details) € in Millions, $ in Millions	Aug. 31, 2012 USD ($)	Nov. 30, 2011 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Mar. 31, 2011 EUR (€)	Mar. 31, 2011 USD ($)	Sep. 30, 2010	Mar. 31, 2010 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Oct. 31, 2011	Dec. 31, 2010 USD ($)
Net product sales					$ 5,301.2		$ 5,971.7					$ 16,170.5	$ 17,748.1
Collaboration and other revenue					142.1		176.2					475.5	491.8
Revenue					5,443.3		6,147.9					16,646.0	18,239.9
Research and development					1,342.8		1,280.9					3,815.0	3,665.5
Collaborative Arrangement, Income Statement Classification and Amounts					65.2		58.6					211.0	155.5
Proceeds from prepayment of revenue-sharing obligation												1,212.1	0.0
Acquired in-process research and development					0.0		0.0					0.0	388.0
Other Nonoperating Income (Expense)					22.0		(60.6)					(5.5)	(71.8)
Erbitux [Member]
Net product sales					6.2		16.2					69.0	61.2
Collaboration and other revenue					80.4		81.1					241.0	240.1
Revenue					86.6		97.3					310.0	301.3
Amylin [Member]
Proceeds from prepayment of revenue-sharing obligation	$ 1,210.0
Other Nonoperating Income (Expense)					787.8		0.0					787.8	0.0
Exenatide [Member]
Net product sales					49.5		46.4					151.1	131.9
Collaboration and other revenue					4.7		60.3					70.1	180.5
Revenue					54.2		106.7					221.2	312.4
Boerhringer Ingelheim (BI) [Member]
Acquired in-process research and development									$ 388.0
Sales NEW [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations Percent		15.00%
Sales NEW [Member] \| Exenatide [Member]
Collaborative Arrangement, Rights and Obligations Percent														100.00%
Revenue Share [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations	$ 1,260.0	$ 1,200.0
Revenue Share [Member] \| Exenatide Once Weekly [Member]
Deferred Revenue, Current					$ 490.0							$ 490.0
Secured Note [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations		$ 1,200.0
Secured Note, Interest Rate [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations Percent		9.50%
Gross Margin Share [Member] \| Exenatide [Member]
Collaborative Arrangement, Rights and Obligations Percent														50.00%
Profit and Development and Marketing Share [Member] \| Effient [Member]
Collaborative Arrangement, Rights and Obligations Percent										50.00%
Selling and Marketing Expense [Member] \| Necitumumab [Member]
Collaborative Arrangement, Rights and Obligations Percent											50.00%
Prepaid Selling and Marketing Expense [Member] \| Duloxetine BI [Member]
Collaborative Arrangement, Rights and Obligations											$ 400.0
Research and Development Exp [Member] \| Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations Percent			30.00%
Research and Development Exp [Member] \| United States [Member] \| Necitumumab [Member]
Collaborative Arrangement, Rights and Obligations Percent											45.00%
Research and Development Exp [Member] \| Outside the United States [Member] \| Necitumumab [Member]
Collaborative Arrangement, Rights and Obligations Percent											72.50%
Research and Development and Marketing and Selling Expense [Member] \| Exenatide [Member]
Collaborative Arrangement, Rights and Obligations Percent														50.00%
Milestone Payments, Development and Regulatory [Member] \| Necitumumab [Member]
Collaborative Arrangement, Rights and Obligations											$ 250.0
Milestone Payments, Development and Regulatory [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations		$ 150.0
Milestone Payments, Development and Regulatory [Member] \| BI compounds [Member]
Collaborative Arrangement, Rights and Obligations								€ 300.0					$ 478.7
Milestone Payments, Development and Regulatory [Member] \| LLY compounds [Member]
Collaborative Arrangement, Rights and Obligations									650.0
Milestone Payments, Development and Regulatory [Member] \| LLY optional compound [Member]
Collaborative Arrangement, Rights and Obligations									$ 525.0
Milestone Payments, Development and Regulatory [Member] \| Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations			$ 515.0	$ 50.0											$ 49.0
Milestone Payments, Sales-based [Member] \| TPG-Axon [Member]
Collaborative Arrangement, Rights and Obligations							$ 70.0
Milestone Payments, Sales-based [Member] \| Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations			$ 150.0
Royalty [Member] \| Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations Percent			20.00%
Loan Commitment [Member] \| Exenatide Once Weekly [Member]
Collaborative Arrangement, Rights and Obligations						$ 165.0
Upfront Payment [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations		$ 250.0
Profit Share [Member] \| Necitumumab [Member]
Collaborative Arrangement, Rights and Obligations Percent											45.00%
Termination Payments [Member] \| United States [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations Percent		65.00%
Termination Payments [Member] \| Outside the United States [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations Percent		35.00%

Asset Impairments, Restructuring, and Other Special Charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Asset impairments, restructuring, and other special charges	$ 53.3	$ 25.2	$ 77.1	$ 233.8

Financial Instruments (Details) € in Millions, £ in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 EUR (€)	Sep. 30, 2012 GBP (£)	Sep. 30, 2012 USD ($)	Dec. 31, 2011 USD ($)
Liabilities, Fair Value Disclosure, Nonrecurring							$ 66.9	$ 121.6
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets	85.00%
Maximum Remaining Maturity of Foreign Currency Derivatives			30 days
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate					100.00%	100.00%	100.00%
Description of Derivative Activity Volume Percent					60.00%	60.00%	60.00%
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net							$ 9.0
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion	$ 2.3	$ 2.3	$ 6.7	$ 6.7
Derivative Instruments, Gain (Loss) Recognized in Income, Net	(23.7)	(51.7)	(38.5)	(1.0)
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net		15.5	0.0	41.2
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	50.0
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value							5,440.0
Available-for-sale Securities, Gross Unrealized Gains							150.6	103.0
Available-for-sale Securities, Gross Unrealized Losses							34.7	80.0
Available-for-sale Securities, Continuous Unrealized Gain Position, Fair Value							5,050.6	2,498.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value							942.3	2,164.4
Other than Temporary Impairment Losses, Investments	0.8	10.9	8.2	17.9
Proceeds from Sale and Maturity of Available-for-sale Securities	1,698.8	775.7	5,334.1	1,274.2
Available-for-sale Securities, Gross Realized Gains	43.1	25.6	70.0	113.6
Available-for-sale Securities, Gross Realized Losses	2.2	2.5	7.4	7.6
Hedged Fixed-Rate Debt [Member]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	12.1	245.4	43.8	255.7
Interest Rate Contract [Member]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	$ (12.1)	$ (245.4)	$ (43.8)	$ (255.7)
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Cash and Cash Equivalents, Fair Value Disclosure							5,319.2	5,922.5
Long-term Debt							(5,520.0)	(6,981.5)
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total							1,580.7	974.6
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Noncurrent, Total							5,224.3	4,029.8
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| Interest Rate Contract [Member]
Derivative Assets, Current								6.1
Derivative Assets, Noncurrent							581.7	531.7
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| Foreign Exchange Contract [Member]
Derivative Assets, Current								16.2
Derivative Assets, Noncurrent							7.0
Derivative Liabilities, Current							(18.4)	(25.9)
Available-for-Sale Securities, Amortized Cost [Member]
Cash and Cash Equivalents, Fair Value Disclosure							5,319.2	5,922.5
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total							1,578.7	975.0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Noncurrent, Total							5,110.4	4,006.4
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents, Fair Value Disclosure							5,235.3	5,264.6
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents, Fair Value Disclosure							83.9	657.9
Long-term Debt							(6,072.2)	(7,451.5)
Fair Value, Inputs, Level 2 [Member] \| Interest Rate Contract [Member]
Derivative Assets, Current								6.1
Derivative Assets, Noncurrent							581.7	531.7
Fair Value, Inputs, Level 2 [Member] \| Foreign Exchange Contract [Member]
Derivative Assets, Current								16.2
Derivative Assets, Noncurrent							7.0
Derivative Liabilities, Current							(18.4)	(25.9)
Estimate of Fair Value, Fair Value Disclosure [Member]
Cash and Cash Equivalents, Fair Value Disclosure							5,319.2	5,922.5
Long-term Debt							(6,072.2)	(7,451.5)
Estimate of Fair Value, Fair Value Disclosure [Member] \| Interest Rate Contract [Member]
Derivative Assets, Current								6.1
Derivative Assets, Noncurrent							581.7	531.7
Estimate of Fair Value, Fair Value Disclosure [Member] \| Foreign Exchange Contract [Member]
Derivative Assets, Current								16.2
Derivative Assets, Noncurrent							7.0
Derivative Liabilities, Current							(18.4)	(25.9)
Corporate Debt Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							1,509.1	600.7
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							2,623.8	2,081.3
Corporate Debt Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							1,507.1	601.1
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							2,593.2	2,093.3
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							1,509.1	600.7
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							2,623.8	2,081.3
Corporate Debt Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							1,509.1	600.7
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							2,623.8	2,081.3
US Government Agencies Debt Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							61.0	362.3
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							1,124.1	908.8
US Government Agencies Debt Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							61.0	362.3
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							1,121.1	901.3
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							61.0	351.3
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							885.7	673.5
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current								11.0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							238.4	235.3
US Government Agencies Debt Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							61.0	362.3
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							1,124.1	908.8
Other Debt Obligations [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							10.6	11.6
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							3.3	10.0
Other Debt Obligations [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							10.6	11.6
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							3.3	11.9
Other Debt Obligations [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							10.6	11.6
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							3.3	8.7
Other Debt Obligations [Member] \| Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent								1.3
Other Debt Obligations [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current							10.6	11.6
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							3.3	10.0
Collateralized Mortgage Backed Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							401.6	443.8
Collateralized Mortgage Backed Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							405.3	479.1
Collateralized Mortgage Backed Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							401.6	443.8
Collateralized Mortgage Backed Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							401.6	443.8
Asset-backed Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							676.1	245.0
Asset-backed Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							692.5	253.2
Asset-backed Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							676.1	245.0
Asset-backed Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent							676.1	245.0
Equity Securities, US [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent							183.4	180.8
Equity Securities, US [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent							83.0	107.5
Equity Securities, US [Member] \| Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent							183.4	180.8
Equity Securities, US [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent							183.4	180.8
Equity Method and Other Investments [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Other Long-term Investments							212.0	160.1
Equity Method and Other Investments [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Other Long-term Investments							212.0	$ 160.1
Buy British pound Sell euro [Member]
Notional Amount of Foreign Currency Derivative Purchase Contracts \| £						£ 202.0
Notional Amount of Foreign Currency Derivative Sale Contracts \| €					€ 252.4
Buy US dollar Sell euro [Member]
Notional Amount of Foreign Currency Derivative Purchase Contracts							863.9
Notional Amount of Foreign Currency Derivative Sale Contracts \| €					669.9
Buy euro Sell US dollar [Member]
Notional Amount of Foreign Currency Derivative Purchase Contracts \| €					€ 892.2
Notional Amount of Foreign Currency Derivative Sale Contracts							$ 1,160.0

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Millions	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Allocated Share-based Compensation Expense	$ 34.4	$ 36.5	$ 100.3	$ 110.7
Stock-based compensation expense			100.3	$ 110.7
Performance Awards, General [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	29.9		$ 29.9
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition			12 months
Shareholder Value Awards [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	60.1		$ 60.1
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition			22 months
Restricted Stock Unit [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 66.5		$ 66.5
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition			23 months

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

Shareholders' Equity (Details) - USD ($)	9 Months Ended	12 Months Ended
Shareholders' Equity (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2000
Stockholders' Equity Note [Abstract]
Treasury Stock, Value, Acquired, Cost Method	$ 0
Stock Repurchase Program, Authorized Amount		$ 3,000,000,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 419,200,000

- Definition

Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.

+ References + Details

Retirement Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Retirement Benefits (Details) - USD ($) $ in Millions	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Service Cost	$ 66.7	$ 57.7	$ 193.8	$ 174.7
Defined Benefit Plan, Interest Cost	113.0	111.8	338.7	335.8
Defined Benefit Plan, Expected Return on Plan Assets	(171.2)	(171.9)	(512.6)	(515.2)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0.8	2.2	2.5	6.9
Defined Benefit Plan, Actuarial Gain (Loss)	71.4	50.4	213.3	149.2
Defined Benefit Plan, Net Periodic Benefit Cost, Total	80.7	50.2	235.7	151.4
Pension and Other Postretirement Benefit Contributions			60.0
Defined Benefit Plan, Estimated Future Employer Contributions in Current Fiscal Year	10.0		10.0
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Service Cost	16.1	14.4	48.4	43.1
Defined Benefit Plan, Interest Cost	28.6	29.5	85.6	88.6
Defined Benefit Plan, Expected Return on Plan Assets	(31.8)	(31.9)	(95.4)	(95.7)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(8.8)	(10.7)	(26.3)	(32.2)
Defined Benefit Plan, Actuarial Gain (Loss)	24.6	22.2	72.9	66.5
Defined Benefit Plan, Net Periodic Benefit Cost, Total	$ 28.7	$ 23.5	85.2	$ 70.3
Pension and Other Postretirement Benefit Contributions			$ 340.0

Contingencies (Details) - Product Liability Litigation [Member]	6 Months Ended	9 Months Ended
	Jun. 30, 2013	Sep. 30, 2012
Zyprexa [Member]
Loss Contingency, Number of Lawsuits		10
Loss Contingency, Number of Plaintiffs		75
Byetta [Member]
Loss Contingency, Number of Lawsuits		115
Loss Contingency, Number of Plaintiffs		500
Loss Contingency, Number of Claimants		500
Loss Contingency, Number of Cases	2
Diethylstilbestrol (DES) [Member]
Loss Contingency, Number of Lawsuits		90
Loss Contingency, Number of Claimants		90
Damages from Product, Breast Cancer [Member] \| Diethylstilbestrol (DES) [Member]
Loss Contingency, Number of Plaintiffs		5
Loss Contingency, Number of Claimants		80
Loss Contingency, Number of Cases		5
California [Member] \| Byetta [Member]
Loss Contingency, Number of Lawsuits		100
Loss Contingency, Number of Plaintiffs		485

Other - Net, Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Component of Other Income, Nonoperating [Line Items]
Income related to prepayment of revenue-sharing obligation	$ (787.8)	$ 0.0	$ (787.8)	$ 0.0
Interest Expense	47.0	45.0	135.3	135.9
Investment Income, Interest	(25.7)	(22.2)	(79.0)	(55.5)
Other (income)expense	(22.0)	60.6	5.5	71.8
Nonoperating Income (Expense), Total	$ 788.5	$ (83.4)	$ 726.0	$ (152.2)